Expanded use of rituximab in the management of non-Hodgkin lymphoma

Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemente...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichenauer, Dennis A, Engert, Andreas, Schulz, Holger
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886316/
https://www.ncbi.nlm.nih.gov/pubmed/20616906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886316/
https://www.ncbi.nlm.nih.gov/pubmed/20616906

Ejemplares similares